rxstatShortages › Octreotide

Octreotide shortage status

Partial shortage

Source: Health Canada shortage reports · Updated Jul 9, 2026

Some Octreotide products are in shortage in Canada (1 of 14 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer.
Products affected
1 / 14
In shortage since
Jun 17, 2024
Reports on file
44
Talk to your pharmacist. Pharmacists can often substitute another manufacturer's version, a different strength, or (in most provinces) adapt or renew a prescription on the spot. Your free provincial health line is 811.

Reports by product

Active shortage
SANDOSTATIN
50MCG · SOLUTION · NOVARTIS PHARMACEUTICALS CANADA INC
DIN 00839191 · since Jun 17, 2024, no end estimate · Disruption of the manufacture of the drug.
Resolved
OCTREOTIDE ACETATE OMEGA
100MCG · SOLUTION · OMEGA LABORATORIES LIMITED
DIN 02248640 · ended May 28, 2026 · Disruption of the manufacture of the drug.
Resolved
OCTREOTIDE ACETATE OMEGA
500MCG · SOLUTION · OMEGA LABORATORIES LIMITED
DIN 02248641 · ended May 12, 2026 · Disruption of the manufacture of the drug.
Resolved
SANDOSTATIN
100MCG · SOLUTION · NOVARTIS PHARMACEUTICALS CANADA INC
DIN 00839205 · ended Jan 31, 2025 · Disruption of the manufacture of the drug.
Discontinued
OCTREOTIDE FOR INJECTABLE SUSPENSION
30MG · POWDER FOR SUSPENSION, SUSTAINED-RELEASE KIT · TEVA CANADA LIMITED
DIN 02503786
Discontinued
OCTREOTIDE FOR INJECTABLE SUSPENSION
20MG · POWDER FOR SUSPENSION, SUSTAINED-RELEASE KIT · TEVA CANADA LIMITED
DIN 02503778
Discontinued
OCTREOTIDE FOR INJECTABLE SUSPENSION
10MG · POWDER FOR SUSPENSION, SUSTAINED-RELEASE KIT · TEVA CANADA LIMITED
DIN 02503751
Resolved
OCTREOTIDE FOR INJECTABLE SUSPENSION
30MG · POWDER FOR SUSPENSION, SUSTAINED-RELEASE KIT · TEVA CANADA LIMITED
DIN 02503786 · ended May 5, 2026 · Disruption of the manufacture of the drug.
Resolved
OCTREOTIDE FOR INJECTABLE SUSPENSION
20MG · POWDER FOR SUSPENSION, SUSTAINED-RELEASE KIT · TEVA CANADA LIMITED
DIN 02503778 · ended May 5, 2026 · Disruption of the manufacture of the drug.
Resolved
OCTREOTIDE FOR INJECTABLE SUSPENSION
10MG · POWDER FOR SUSPENSION, SUSTAINED-RELEASE KIT · TEVA CANADA LIMITED
DIN 02503751 · ended May 5, 2026 · Disruption of the manufacture of the drug.
Resolved
SANDOSTATIN LAR
30MG · POWDER FOR SUSPENSION, SUSTAINED-RELEASE · NOVARTIS PHARMACEUTICALS CANADA INC
DIN 02239325 · ended Mar 4, 2026 · Demand increase for the drug.
Resolved
OCTREOTIDE ACETATE OMEGA
500MCG · SOLUTION · OMEGA LABORATORIES LIMITED
DIN 02248641 · ended Feb 18, 2026 · Disruption of the manufacture of the drug.

Showing 12 of 44 reports. All reports are on file with Health Canada.

What's happening

Octreotide is currently affected by an active shortage report filed with Health Canada by NOVARTIS PHARMACEUTICALS CANADA INC.

The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.

If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.

Octreotide is classified under “HYPOTHALAMIC HORMONES” (ATC H01CB).

Recent changes

Common questions

When will Octreotide be back in stock in Canada?

Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.

Why is Octreotide in shortage?

See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.

What can my pharmacist do about it?

Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.

Related drugs (hypothalamic hormones)

Guides: what to do when your medication is in shortage · how to read shortage reports

Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.